

# EXHIBIT 17

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY  
  
IN RE JOHNSON & JOHNSON TALCUM )  
POWDER PRODUCTS MARKETING, ) MDL NO.  
SALES PRACTICES, AND PRODUCTS ) 16-2738 (MAS) (RLS)  
LIABILITY LITIGATION

\*\*\*\*\*

ORAL DEPOSITION OF  
JUDITH WOLF, M.D.  
APRIL 25, 2024  
(VOLUME 2)

\*\*\*\*\*

ORAL DEPOSITION of JUDITH WOLF, M.D., produced  
as a witness at the instance of the Defendants, and duly  
sworn, was taken in the above-styled and numbered cause  
on the 25th day of April, 2024, from 8:58 a.m. to 11:16  
a.m., before Gabriela S. Silva, CSR, RPR in and for the  
State of Texas, reported by stenograph, at Aloft Austin  
Downtown, 109 East 7th Street, Austin, Texas, pursuant  
to the Federal Rules of Civil Procedure and the  
provisions stated on the record or attached hereto.

<p style="text-align: right;">Page 30</p> <p>1 about probably account for the vast majority of 09:34</p> <p>2 inherited ovarian cancers. 09:34</p> <p>3 Q. From your -- from the research that you did on 09:35</p> <p>4 the SDHA and PTCH1 genes, is it your opinion that 09:35</p> <p>5 medical science has researched those genes sufficiently 09:35</p> <p>6 as it relates to ovarian cancer to rule out that they 09:35</p> <p>7 can affect the risk of developing ovarian cancer? 09:35</p> <p>8 MRS. O'DELL: Object to the form. 09:35</p> <p>9 A. It's my opinion that to date there's no 09:35</p> <p>10 evidence that mutation in SDHA has any increased risk of 09:35</p> <p>11 ovarian cancer. It's also my opinion that the PTCH1 09:35</p> <p>12 gene mutation that she had was a VUS and the vast 09:35</p> <p>13 majorities, they're not found to be associated with 09:35</p> <p>14 anything. And of the pathologic mutations in PTCH1, to 09:35</p> <p>15 date, there hasn't been any association with ovarian 09:35</p> <p>16 cancer. So I think it's highly unlikely. 09:35</p> <p>17 Q. (By Mr. Hegarty) When you were doing your 09:35</p> <p>18 research into those two gene mutations, did you see 09:35</p> <p>19 whether there has been any analysis done as to those 09:36</p> <p>20 mutations and ovarian cancer? 09:36</p> <p>21 A. I'm not aware of that. 09:36</p> <p>22 Q. You note in your report for Mrs. Bondurant on 09:36</p> <p>23 Page 23 that her family history includes a maternal aunt 09:36</p> <p>24 with [REDACTED] and a mother with [REDACTED] 09:36</p> <p>25 Correct? 09:36</p>	<p style="text-align: right;">Page 32</p> <p>1 ovarian cancer? 09:37</p> <p>2 MRS. O'DELL: Object to the form. 09:37</p> <p>3 A. The tests that she had tested for 67, which is 09:37</p> <p>4 probably the most, one of the most, number of genes that 09:37</p> <p>5 we know of at the time she had testing in 2019 that were 09:37</p> <p>6 available. 09:37</p> <p>7 And as I stated before, since we've known 09:37</p> <p>8 about these mutations, the vast majority of them are 09:37</p> <p>9 inherited ovarian cancers or associated with BRCA1 and 09:38</p> <p>10 2. And all the other genes that have been identified 09:38</p> <p>11 since then account for very small portion of inherited 09:38</p> <p>12 ovarian cancers. So could she have a mutation that 09:38</p> <p>13 wasn't tested for? It's possible. Is it likely? No. 09:38</p> <p>14 Q. (By Mr. Hegarty) Do you agree though that based 09:38</p> <p>15 on your review of Mrs. Bondurant's records, it was 09:38</p> <p>16 appropriate for her to have genetic testing? 09:38</p> <p>17 A. I do think it was appropriate for her to have 09:38</p> <p>18 genetic testing. In fact, I refer all of my ovarian 09:38</p> <p>19 cancer patients today to have genetic testing or at 09:38</p> <p>20 least offer it to them. 09:38</p> <p>21 Q. So if she had been your patient at the time of 09:38</p> <p>22 diagnosis, you would've recommended she have genetic 09:38</p> <p>23 testing? 09:38</p> <p>24 A. I don't remember what year she was diagnosed. 09:38</p> <p>25 I'm going to say in 2024, I certainly would recommend 09:38</p>
<p style="text-align: right;">Page 31</p> <p>1 A. Yes. 09:36</p> <p>2 Q. You go on to say that a family history like 09:36</p> <p>3 this was a risk factor for Mrs. Bondurant in developing 09:36</p> <p>4 breast cancer up to 2.0 or two times. Correct? 09:36</p> <p>5 A. Yes. 09:36</p> <p>6 Q. I should say two times or 2.0. Right? 09:36</p> <p>7 A. Correct. 09:36</p> <p>8 Q. Based on this risk tied to family history, do 09:36</p> <p>9 you agree that it does raise the issue of whether Mrs. 09:36</p> <p>10 Bondurant has some type of inherited gene mutation 09:36</p> <p>11 related to ovarian cancer risk? True? 09:36</p> <p>12 A. It's hard to know. That could be one reason 09:36</p> <p>13 for her increased family risk. It also could be 09:37</p> <p>14 something else that the family was exposed to that put 09:37</p> <p>15 them at an increased risk that they were all exposed to. 09:37</p> <p>16 That's all I can say about it, what's in the literature 09:37</p> <p>17 about family history when testing is negative and that's 09:37</p> <p>18 a possibility. 09:37</p> <p>19 Q. Do you agree that Mrs. Bondurant could have an 09:37</p> <p>20 inherited gene mutation that she was not tested for back 09:37</p> <p>21 in 2019? 09:37</p> <p>22 A. I think it's unlikely. It's a possibility, but 09:37</p> <p>23 I think it's highly unlikely. 09:37</p> <p>24 Q. Is it fair to say that the tests that she had 09:37</p> <p>25 couldn't rule out a gene mutation being involved in her 09:37</p>	<p style="text-align: right;">Page 33</p> <p>1 everyone. 09:38</p> <p>2 Q. Please feel free to look at your report. 09:38</p> <p>3 A. Yeah, in 2018, 2018, she was diagnosed in late 09:38</p> <p>4 2018. So I think even at that time, I was recommending 09:39</p> <p>5 everyone have genetic testing. 09:39</p> <p>6 Q. Have you seen patients as follow up to their 09:39</p> <p>7 original cancer diagnosis where they had less than full 09:39</p> <p>8 panel testing years earlier that you recommend be 09:39</p> <p>9 retested with the now full panel testing? 09:39</p> <p>10 A. It's a discussion that I've had with a few 09:39</p> <p>11 patients. It's a complicated issue, I think, because 09:39</p> <p>12 oftentimes it's an expensive test that insurance will 09:39</p> <p>13 pay for a new test. And if they already have the 09:39</p> <p>14 diagnosis and they've tested negative for at least BRCA1 09:39</p> <p>15 and 2, putting them through the cost of a four to 09:39</p> <p>16 6,000-dollar test may or may not be of benefit. 09:39</p> <p>17 So it's an individual discussion that I 09:39</p> <p>18 have with patients and I've had a few go ahead and get 09:39</p> <p>19 tested and some that don't want to get more testing. 09:39</p> <p>20 Q. Turning to Page 22 of Dr. Levy's report, he 09:40</p> <p>21 discusses his review of Anna Gallardo, the genetic 09:40</p> <p>22 testing results. Correct? 09:40</p> <p>23 A. Yes. 09:40</p> <p>24 Q. I will mark as our next exhibit your report 09:40</p> <p>25 from Mrs. Gallardo and her genetic test result. 09:40</p>

Page 90	Page 92
1 Q. And all that is still accurate? 11:16	1 I, JUDITH WOLF, M.D., have read the foregoing
2 A. Yes. 11:16	2 deposition and hereby affix my signature that same is
3 MR. HEGARTY: Those are all the questions I 11:16	3 true and correct, except as noted above.
4 have. 11:16	4
5 RECROSS-EXAMINATION 11:16	5
6 BY MRS. O'DELL: 11:16	6
7 Q. One last follow up. In addition to the 11:16	7 JUDITH WOLF, M.D.
8 specific references in your report to asbestos and 11:16	8 THE STATE OF _____)
9 studies that are pinpoint cited or specifically 11:16	9 COUNTY OF _____)
10 referenced in the body of your report, do you also rely 11:16	10 Before me, _____, on
11 on all the literature regarding asbestos as included in 11:16	11 this day personally appeared JUDITH WOLF, M.D., known to
12 your materials considered? 11:16	12 me (or proved to me under oath or through
13 A. Yes. 11:16	13 _____) (description of identity card or
14 MRS. O'DELL: Thank you. Nothing further. 11:16	14 other document) to be the person whose name is
15 MR. HEGARTY: No further questions. 11:16	15 subscribed to the foregoing instrument and acknowledged
16 COURT REPORTER: Mrs. O'Dell, were you	16 to me that they executed the same for the purposes and
17 going to want a copy of this transcript?	17 consideration therein expressed.
18 MRS. O'DELL: Yes, please.	18 Given under my hand and seal of office this
19 COURT REPORTER: And Mr. Golomb?	19 _____ day of _____, 2024.
20 MR. GOLOMB: I do.	20
21 (Deposition concluded at 11:16 a.m.)	21
22 *-*-SIGNATURE REQUESTED*-*-	22 _____
23	23 Notary Public in and for
24	24 The State of
25	25
Page 91	Page 93
1 CHANGES AND SIGNATURE	1 IN THE UNITED STATES DISTRICT COURT
2 WITNESS NAME: _____ DATE OF DEPOSITION: _____	2 FOR THE DISTRICT OF NEW JERSEY
3 PAGE LINE CHANGE REASON	3 IN RE JOHNSON & JOHNSON TALCUM )
4 _____	4 POWDER PRODUCTS MARKETING, ) MDL NO.
5 _____	5 SALES PRACTICES, AND PRODUCTS ) 16-2738 (MAS) (RLS)
6 _____	6 REPORTER'S CERTIFICATION
7 _____	7 DEPOSITION OF JUDITH WOLF, M.D.
8 _____	8 April 25, 2024
9 _____	9 I, Gabriela S. Silva, Certified Shorthand
10 _____	10 Reporter in and for the State of Texas, hereby certify
11 _____	11 to the following:
12 _____	12 That the witness, JUDITH WOLF, M.D., was duly
13 _____	13 sworn by the officer and that the transcript of the oral
14 _____	14 deposition is a true record of the testimony given by
15 _____	15 the witness;
16 _____	16 I further certify that pursuant to FRCP Rule
17 _____	17 30(f)(1) that the signature of the deponent:
18 _____	18 _____X_____ was requested by the deponent or a party
19 _____	19 before the completion of the deposition and that the
20 _____	20 signature is to be before any notary public and returned
21 _____	21 within 30 days from date of receipt of the transcript.
22 _____	22 If returned, the attached Changes and Signature Page
23 _____	23 contains any changes and the reasons therefor;
24 _____	24 _____ was not requested by the deponent or a party
25 _____	25 before the completion of the deposition.
	26 I further certify that I am neither counsel
	27 for, related to, nor employed by any of the parties or
	28 attorney in the action in which this proceeding was
	29 taken, and further that I am not financially or
	30 otherwise interested in the outcome of the action.
	31 Certified to by me this _____ day of
	32 _____, 2024.
	33 <%23035,Signature%>
	34
	35